Paliperidone Genericon (Paliperidone)

Paliperidone is an atypical antipsychotic that acts on dopamine and serotonin pathways to manage psychotic disorders.

• Schizophrenia: reduces acute psychotic symptoms and helps maintain long‑term stability.
• Schizoaffective disorder: alleviates both mood and psychotic components of the illness.
• Maintenance therapy: prevents relapse of psychotic episodes when used as a long‑acting injectable.
• Adjunctive treatment: may be added to oral regimens when rapid symptom control is needed.
• Acute exacerbations: provides rapid plasma levels for quick symptom control in hospital settings.
• Long‑term management: supports adherence by reducing the need for daily oral dosing.

• Paliperidone blocks dopamine D2 receptors and serotonin 5‑HT2A receptors in the central nervous system, reducing dopaminergic neurotransmission that underlies psychotic symptoms while modulating serotonergic activity to improve mood and cognition. This dual antagonism helps stabilize neuronal signaling pathways implicated in schizophrenia and schizoaffective disorder.

Paliperidone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Injection site pain: localized discomfort at the administration site.
• Weight gain: gradual increase in body weight.
• Drowsiness: feeling unusually sleepy or fatigued.
• Constipation: reduced bowel movements.
• Dry mouth: decreased salivation.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction.
• Tardive dyskinesia: persistent involuntary movements.
• Seizures: increased risk in susceptible individuals.
• Orthostatic hypotension: sudden drop in blood pressure upon standing.
• Hyperglycemia: elevated blood glucose levels.
• Cardiac arrhythmias: irregular heart rhythms.

When prescribing Paliperidone Genericon, clinicians should consider several safety factors.

• Cardiovascular assessment: evaluate for history of arrhythmias or orthostatic hypotension.
• Metabolic monitoring: check glucose and lipid levels regularly.
• Neurological evaluation: screen for movement disorders or seizure risk.
• Pregnancy and lactation: avoid use unless benefits outweigh risks.
• Drug interactions: review concomitant medications for potential CYP450 effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase paliperidone plasma concentrations and toxicity.
• QT‑prolonging agents: combined use can heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants: may enhance sedation and dizziness.
• Antihypertensives: could potentiate orthostatic hypotension.
• Antidiabetic drugs: may affect glucose control.
• Anticholinergic agents: could worsen constipation.
• Herbal supplements (e.g., St. John’s wort): may alter drug metabolism.